Suppliers / Jiangsu Weiqida Pharmaceutical

Jiangsu Weiqida Pharmaceutical

China Updated 9 July 2026

Jiangsu Weiqida Pharmaceutical is an API manufacturer based in China. It holds one active US drug master file and 3 valid CEPs across a filed portfolio of 3 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 21 March 2025 as VAI.

1
active US DMFs
3
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 March 2025 VAI US FDA
  • 15 December 2017 VAI US FDA
  • 30 April 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Nantong City, China Not on file
China, China 3008245746

What they file, and where

Molecule Regulators Docs
Azithromycin EDQM, SFDA (Saudi Arabia), US FDA 3
Abacavir EDQM 1
Nebivolol EDQM 1

Also appears on these molecule pages

Abacavir API Azithromycin API Nebivolol API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Jiangsu Weiqida Pharmaceutical

Does Jiangsu Weiqida Pharmaceutical hold a US DMF or a CEP?
Jiangsu Weiqida Pharmaceutical holds 1 active US drug master file and 3 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Jiangsu Weiqida Pharmaceutical FDA-registered?
One site operated by Jiangsu Weiqida Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Jiangsu Weiqida Pharmaceutical's last inspection go?
The most recent inspection on record closed on 21 March 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 3 inspections are on file.
Where does Jiangsu Weiqida Pharmaceutical manufacture?
2 registered sites are on record, in China (Nantong City and China). Every site is listed on this page with the register it came from.
What does Jiangsu Weiqida Pharmaceutical make?
3 molecules are on record against Jiangsu Weiqida Pharmaceutical, including Azithromycin, Abacavir and Nebivolol. Each links through to that molecule's full manufacturer list.
Which regulators recognise Jiangsu Weiqida Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Jiangsu Weiqida Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 21 March 2025.

Comparable suppliers

Hetero shares 2 molecules Lupin shares 2 molecules Apitoria Pharma shares 1 molecule Cipla shares 1 molecule Dr Reddy's Laboratories shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates